OSM and metabolic dysfunction-associated steatotic liver disease: In our knowledge, this is the first report involving up-regulation of OSM expression in experimental and clinical progressive NAFLD, and further experiments and analyses are currently in progress in order to verify whether this mediator (or its related receptor subunits) may be validated as a marker of NAFLD progression and/or may have prognostic significance.